Koyo Tsujikawa

Koyo Tsujikawa

Auto-generated profile, based on publicly available information

Koyo Tsujikawa

Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2015 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
KTKoyo Tsujikawa
Koyo Tsujikawa
YHYasuhiro Hasegawa
Yasuhiro Hasegawa
SYSatoshi Yokoi
Satoshi Yokoi
KYKeizo Yasui
Keizo Yasui
INIchiro Nanbu
Ichiro Nanbu
ATAkira Takahashi
Akira Takahashi
Objectives The aim of this study was to investigate chronological changes of 123I-meta-iodobenzylguanidine (MIBG) myocardial scintigraphy and its relation to clinical features in patients with Parkinson's disease (PD), and to characterise patients with PD with normal or mildly low MIBG uptakes at their early stages. Methods The participants were 70 patients with PD who underwent 123I-MIBG myocardial scintigraphy twice or more. A cluster analysis was performed using parameters calculated from heart to mediastinum (H/M) ratio and washout ratio (WR). Results At baseline, the mean early H/M ratio (H/M(E)), delayed H/M ratio (H/M(D)) and WR were 1.83, 1.69 and 41.7%, respectively. After a mean interval of 3.0 years, follow-up studies showed significantly declined H/M(E) (1.69, p<0.001), declined H/M(D) (1.47, p<0.001) and enhanced WR (43.8%, p=0.007). Our longitudinal observations revealed that there existed heterogeneous changes in MIBG uptakes among patients. The cluster analysis classified the patients into two subgroups: 42 patients with markedly low MIBG uptakes at baseline (group A) and 28 patients with normal or mildly low MIBG uptakes at baseline (group B). Group B showed a significantly higher ratio of females, younger age at onset, lower Hoehn and Yahr stage and less demented, compared with group A. Conclusions Follow-up studies of MIBG divided the patients with PD into two major subgroups. A subgroup of patients with PD with normal or mildly low MIBG uptakes at the early stages of illness was characterised by female-dominant, young onset, slow progression in motor dysfunctions and preserved cognitive function. Trial registration number 1033.

27 May 2022 in Science Advances
Verified
Journal Article
Open access
KTKoyo Tsujikawa
Koyo Tsujikawa
KHKohei Hamanaka
Kohei Hamanaka
YRYuichi Riku
Yuichi Riku
YHYuki Hattori
Yuki Hattori
NHNorikazu Hara
Norikazu Hara
MKMasahisa Katsuno
Masahisa Katsuno
While amyloid-β lies upstream of tau pathology in Alzheimer’s disease, key drivers for other tauopathies, including progressive supranuclear palsy (PSP), are largely unknown. Various tau mutations are known to facilitate tau aggregation, but how the nonmutated tau, which most cases with PSP share, increases its propensity to aggregate in neurons and glial cells has remained elusive. Here, we identified genetic variations and protein abundance of filamin-A in the PSP brains without tau mutations. We provided in vivo biochemical evidence that increased filamin-A levels enhance the phosphorylation and insolubility of tau through interacting actin filaments. In addition, reduction of filamin-A corrected aberrant tau levels in the culture cells from PSP cases. Moreover, transgenic mice carrying human filamin-A recapitulated tau pathology in the neurons. Our data highlight that filamin-A promotes tau aggregation, providing a potential mechanism by which filamin-A contributes to PSP pathology.

3 May 2023 in Neuroscience Research
Verified
Journal Article
Closed access
MKMayumi Kataoka
Mayumi Kataoka
KSKentaro Sahashi
Kentaro Sahashi
KTKoyo Tsujikawa
Koyo Tsujikawa
JTJun-Ichi Takeda
Jun-Ichi Takeda
THTomoki Hirunagi
Tomoki Hirunagi
MKMasahisa Katsuno
Masahisa Katsuno

25 February 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
JLJiayi Li
Jiayi Li
YIYohei Iguchi
Yohei Iguchi
KYKenji Yoshida
Kenji Yoshida
DKDaisuke Kato
Daisuke Kato
KAKunihiko Araki
Kunihiko Araki
MKMasahisa Katsuno
Masahisa Katsuno
Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) develop as spatial pathologies in which neurons and glial cells are interconnected. TAR DNA-binding protein 43 (TDP-43) is a major pathological protein that is inextricably associated with ALS and FTLD. In this study, we investigated the roles of neuronal TDP-43 in neuron–oligodendrocyte interactions using neuron-specific TDP-43 knockout (TDP-43cKO) mice. TDP-43 depletion in neurons induced hypomyelination, which was confirmed by immunohistochemistry and ultrastructural analysis. In addition, conduction disturbance was revealed by electrophysiological analysis. The hypomyelination of TDP-43cKO mouse was restored by cytoplasmic TDP-43 supplementation in neurons. Neuron-specific transcriptome analysis revealed that neurexin 1 (NRXN1) is the regulatory target of TDP-43, which promotes myelin formation. The hypomyelination of TDP-43cKO mice was also restored by NRXN1b supplementation in neurons. We further confirmed that TDP-43 stabilizes Nrxn1 mRNA by binding to the Nrxn1 3’untranslated region (3’UTR). Although TDP-43cKO exhibited impaired recognition memory, the supplementation of NRXN1 in the hippocampus recovered the memory disturbances. In conclusion, this study demonstrates the neuron–oligodendrocyte interaction mediated by neuronal TDP-43 via NRXN1 mRNA stabilization. These findings shed light on neuron–oligodendrocyte interaction in the disease mechanisms of ALS/FTLD.

27 August 2026 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
NNNatsuki Nakamura
Natsuki Nakamura
YNYosuke Nishio
Yosuke Nishio
HNHiromi Nyuzuki
Hiromi Nyuzuki
AFAi Fukushima
Ai Fukushima
MMMasaki Miura
Masaki Miura
TOTomoo Ogi
Tomoo Ogi
Background: Biallelic variants in VPS41 , encoding a subunit of the HOPS complex, cause autosomal recessive spinocerebellar ataxia 29 (SCAR29), a rare neurodevelopmental disorder with an incompletely defined phenotypic and molecular spectrum. Methods: We investigated a 24‐year‐old man with cerebellar ataxia, hypotonia, and intellectual disability. Exome sequencing identified four candidate VPS41 variants. Because maternal DNA was unavailable, long‐read genome sequencing was performed to determine allelic configuration, followed by RNA and protein analyses. Results: In addition to typical SCAR29 features, the patient showed previously unreported findings, including swan‐neck deformities and pes cavus. Long‐read genome sequencing demonstrated that two VPS41 variants were in trans. RNA analysis revealed distinct splicing consequences: one allele produced an out‐of‐frame transcript predicted to undergo nonsense‐mediated decay, whereas the other generated an in‐frame exon‐skipped transcript. These complementary defects reduced VPS41 expression at both transcript and protein levels, supporting pathogenicity and variant reclassification. Conclusion: Our findings expand the phenotypic spectrum of VPS41 ‐related disease and highlight the value of long‐read allelic resolution in clarifying pathogenic mechanisms in rare genetic disorders.

26 October 2026 in medRxiv
Verified
Preprint
Open access
PDF file
KOKazuki Obara
Kazuki Obara
AMAndrea Mastrangelo
Andrea Mastrangelo
ARAgustina Ranieri
Agustina Ranieri
SJShorena Janelidze
Shorena Janelidze
DIDaisuke Ito
Daisuke Ito
NMNiklas Mattsson-Carlgren
Niklas Mattsson-Carlgren
Background: α-synuclein (Lewy body-type) co-pathology has been identified at autopsy in a subset of patients with amyotrophic lateral sclerosis (ALS). However, its prevalence and prognostic relevance in vivo remain poorly characterized. Methods: We analyzed baseline cerebrospinal fluid (CSF) α-synuclein seed amplification assay (αSyn SAA) status in 443 patients with ALS from two cohorts (Nagoya, Japan, n = 248; Bologna, Italy, n = 195). Samples were classified as strong-positive, weak-positive, or negative based on RT-QuIC reactivity across replicate wells, using the assay’s established a priori criteria at initial and repeat testing; classifications were corroborated by quantitative kinetic parameters. We compared age– and sex-adjusted odds of positivity in ALS with those in cognitively unimpaired (CU; n = 999; stratified by amyloid-β [Aβ] status), Aβ-positive mild cognitive impairment ( n = 224), and Alzheimer’s disease dementia ( n = 319) groups from the Swedish BioFINDER cohort. In ALS, we examined tracheostomy-free survival and longitudinal functional decline using cohort-stratified Cox and linear mixed-effects models, respectively. We also assessed interactions between αSyn SAA status and baseline CSF neurofilament light chain (NfL). Prognostic analyses were performed in sporadic ALS and repeated after including familial or genetic cases. Results: Strong αSyn SAA positivity was detected in 24/443 patients with ALS (5.4%); overall positivity, including weak-positive samples, was 37/443 (8.4%). Patients with ALS did not have significantly higher odds of SAA positivity than Aβ-negative CU participants (age– and sex-adjusted odds ratio [OR] 1.33, 95% CI [0.82, 2.14]) and had significantly lower odds than patients with Alzheimer’s disease dementia (OR 0.44, [0.27, 0.70]). Among patients with sporadic ALS, strong αSyn SAA positivity was associated with shorter tracheostomy-free survival after adjustment for established predictors including NfL (adjusted HR 2.08 [1.25, 3.45]), whereas weak positivity showed no clear survival association. In linear mixed-effects models, strong αSyn SAA positivity modified the association between NfL and ALSFRS-R decline (NfL × αSyn SAA × time interaction β−0.70 points/month [−1.26, −0.14] per SD NfL). These findings persisted in analyses including familial or genetic ALS cases and in those restricted to Aβ-negative patients. Neuropathological findings ( n = 5) were concordant with the CSF αSyn SAA classification. Conclusions: A strong α-synuclein seeding profile was uncommon in ALS but identified a subgroup with shorter survival and a stronger association between NfL and functional decline. These findings provide ante-mortem evidence that α-synuclein co-pathology may contribute to prognostic heterogeneity in ALS.